immatics biotechnologies

About:

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.

Website: https://immatics.com

Twitter/X: immatics

Top Investors: Moderna, KfW, Amgen, Bristol-Myers Squibb, Perceptive Advisors

Description:

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.